Hydroxyprogesterone caproate is a Small Molecule owned by Lipocine, and is involved in 5 clinical trials, of which 4 were completed, and 1 is planned.

LPCN-1107 is an agent for the treatment of preterm birth. It is natural progestogen. Progestogens are synthetic forms of progesterone. Progesterone is a naturally occurring hormone which is essential to maintain pregnancy. As the levels of progesterone secreted by the placenta drop off, this action that stimulates the beginning of the contractions that will lead to birth. By giving progesterone to women with a short cervix prolong the stimulation and beginning of contraction. Progesterone relaxes uterine smooth muscle and the labor is prolonged.

The revenue for Hydroxyprogesterone caproate is expected to reach a total of $127m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Hydroxyprogesterone caproate NPV Report.

Hydroxyprogesterone caproate is currently owned by Lipocine.

Hydroxyprogesterone caproate Overview

Hydroxyprogesterone caproate (LPCN-1107) is under development for the prevention of preterm birth. LPCN-1107 is human progestogen and acts by targeting  progesterone receptor. The drug candidate is administered through oral route. It is based on Lip'ral technology.

Lipocine Overview

Lipocine operates as a pharmaceutical company that develops and commercializes treatments for men’s and women’s health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021, and for women’s health include LPCN 1107. It’s LPCN 1111 is an oral testosterone product candidate and LPCN 1021 is an oral testosterone replacement therapy with a positive topline. Lipocine offers LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of preterm birth. It develops patented technology based on lipidic compositions that form an optimal dispersed phase in the gastrointestinal environment for improved absorption of the insoluble drug. Its Lip’ral is a technology based on lipidic compositions that form optimal dispersed phases in the gastrointestinal environment. Lipocine is headquartered in Salt Lake City, Utah, US

The company reported revenues of (US Dollars) US$16.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$0.9 million in FY2021, compared to an operating loss of US$17.8 million in FY2020. The net loss of the company was US$0.6 million in FY2021, compared to a net loss of US$21 million in FY2020.

Quick View – Hydroxyprogesterone caproate

Report Segments
  • Innovator
Drug Name
  • Hydroxyprogesterone caproate
Administration Pathway
  • Oral
Therapeutic Areas
  • Women’s Health
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.